Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 3 de 3
Filtre
1.
J. Bras. Patol. Med. Lab. (Online) ; 55(3): 289-294, May-June 2019. graf
Article Dans Anglais | LILACS-Express | LILACS | ID: biblio-1012488

Résumé

ABSTRACT Nodular fasciitis (NF) is a rare fibroblast proliferation of unknown etiology, with benign, rapid clonal growth, from a superficial fascia to the subcutaneous tissue or an adjacent muscular layer. Also known as pseudosarcomatous fasciitis, this clinical syndrome is characterized as a solitary mass of hardened consistency, painless palpation and no gender preference. The definitive diagnosis is made by immunohistochemistry and surgery is the treatment of choice.


RESUMEN La fascitis nodular (FN) es una lesión proliferativa fibroblástica rara, de etiología desconocida, naturaleza benigna, crecimiento rápido y probablemente clonal, que se origina en una fascia superficial hacia el tejido subcutáneo o una camada muscular adyacente. También conocida como fascitis pseudosarcomatosa, este síndrome clínico se caracteriza por un tumor solitario de consistencia endurecida, ligero dolor a la palpación y sin predilección por sexo. Su diagnóstico definitivo se hace por inmunohistoquímica, y el tratamiento de elección es el quirúrgico.


RESUMO A fasciíte nodular (FN) é uma lesão proliferativa fibroblástica rara, de etiologia desconhecida, caráter benigno, crescimento rápido e provavelmente clonal, que se origina a partir de uma fáscia superficial para o tecido subcutâneo ou uma camada muscular adjacente. Também conhecida como fasciíte pseudossarcomatosa, esta síndrome clínica caracteriza-se por uma massa solitária de consistência endurecida, pouco dolorosa à palpação e sem predileção por gênero. O diagnóstico definitivo é feito por imuno-histoquímica, e o tratamento de escolha é o cirúrgico.

2.
Obstetrics & Gynecology Science ; : 525-529, 2015.
Article Dans Anglais | WPRIM | ID: wpr-72976

Résumé

Aggressive angiomyxoma, a rare soft tissue benign neoplasm, predominantly occurs in the female pelvic peritoneum and perineum region during reproductive age. It is slow growing, locally infiltrative, and has a high risk of local recurrence and the neoplastic character of blood vessels. The standard treatment is surgery. We report three unusual aggressive angiomyxoma cases. The first case was a pedunculated mass of the left labium major; the second, a left perineal mass that infiltrated into the paravesical area via the obturator foramen; and the third, a big mass in the retroperitoneal cavity, found that growing aggressive angiomyxoma looked like lava expulsion in the pelvic area. After a thorough examination and full radiologic workup, we performed surgical excision in each patient via different approaches. Histopathologic findings were consistent with diagnosis of aggressive angiomyxoma. To date, no relapse has been observed.


Sujets)
Femelle , Humains , Vaisseaux sanguins , Diagnostic , Procédures de chirurgie gynécologique , Myxome , Tumeurs du tissu conjonctif , Périnée , Péritoine , Récidive , Tumeurs du rétropéritoine , Tumeurs de la vulve
3.
Clinics ; 64(11): 1059-1064, Nov. 2009. graf, tab
Article Dans Anglais | LILACS | ID: lil-532532

Résumé

INTRODUCTION AND OBJECTIVE: Neoadjuvant and adjuvant therapies for soft tissue sarcomas of the extremities are still controversial. The aim of this study was to analyze the results of a protocol of neoadjuvant chemoradiation therapy for extremity sarcomas. METHODS: A retrospective analysis was carried out in a consecutive series of 49 adult patients with advanced extremity soft tissue sarcomas that could not be resected with adequate margins during the primary resection. All patients were treated with a protocol of preoperative radiation therapy at a total dose of 30 Gy, concomitant with doxorubicin (60 mg/m²) chemotherapy. The main endpoints assessed were local recurrence-free survival, metastasis-free survival and overall survival. The median follow-up time was 32.1 months. RESULTS: The five-year local recurrence-free survival, metastasis-free survival and overall survival rates were 81.5 percent, 46.7 percent and 58.3 percent, respectively. For high-grade tumors, the five-year metastasis-free and overall survival rates were only 36.3 percent and 41.2 percent, respectively. Severe wound complications were observed in 41.8 percent of the patients who underwent surgery. These complications precluded adjuvant chemotherapy in 73.7 percent (14/19) of the patients eligible to receive it. CONCLUSIONS: In this study, neoadjuvant chemoradiation therapy was associated with a good local control rate, but the distant relapse-free rate and overall survival rate were still poor. The high rate of wound complications modified the planning of adjuvant treatment in most patients.


Sujets)
Adolescent , Adulte , Sujet âgé , Femelle , Humains , Mâle , Adulte d'âge moyen , Jeune adulte , Traitement néoadjuvant/effets indésirables , Sarcomes/mortalité , Tumeurs des tissus mous/mortalité , Traitement médicamenteux adjuvant/effets indésirables , Doxorubicine/effets indésirables , Méthodes épidémiologiques , Membres , Récidive tumorale locale , Radiothérapie adjuvante/effets indésirables , Sarcomes/thérapie , Tumeurs des tissus mous/thérapie , Résultat thérapeutique , Jeune adulte
SÉLECTION CITATIONS
Détails de la recherche